for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

FibroGen Inc

FGEN.O

Latest Trade

10.92USD

Change

0.06(+0.55%)

Volume

120,283

Today's Range

10.83

 - 

11.05

52 Week Range

9.88

 - 

57.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.86
Open
10.86
Volume
120,283
3M AVG Volume
26.05
Today's High
11.05
Today's Low
10.83
52 Week High
57.21
52 Week Low
9.88
Shares Out (MIL)
92.62
Market Cap (MIL)
1,005.87
Forward P/E
-3.90
Dividend (Yield %)
--

Next Event

Q3 2021 FibroGen Inc Earnings Release

Latest Developments

More

Astellas Receives European Commission Approval For First-In-Class Evrenzo (Roxadustat) For Adult Patients With Symptomatic Anemia Of Chronic Kidney Disease

Fibrogen Announces Retirement Of Pat Cotroneo And Appointment Of Juan Graham As CFO

FibroGen Receives Complete Response Letter From The FDA For Roxadustat For Anemia Of Chronic Kidney Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Industry

Business Services

Contact Info

409 Illinois St

SAN FRANCISCO, CA

94158-2509

United States

+1.415.9781200

http://www.fibrogen.com

Executive Leadership

James A. Schoeneck

Chairman of the Board

Enrique A. Conterno

Chief Executive Officer, Director

Juan Graham

Chief Financial Officer

Christine L. Chung

Senior Vice President, China Operations

Elias Kouchakji

Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance

Key Stats

2.90 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.3K

2020

0.2K

2021(E)

0.3K
EPS (USD)

2018

-1.030

2019

-0.890

2020

-2.110

2021(E)

-2.785
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.85
Price To Book (MRQ)
3.86
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.03
LT Debt To Equity (MRQ)
7.02
Return on Investment (TTM)
-36.56
Return on Equity (TTM)
-28.67

Latest News

Latest News

U.S. FDA declines to approve FibroGen's anemia drug

FibroGen Inc said said on Wednesday that the U.S. Food and Drug Administration has declined to approve its treatment for anemia of chronic kidney disease, citing the need for an additional clinical study.

BRIEF-Fibrogen Says On July 8, Units And Astrazeneca Entered Into An Amendment To Amended And Restated License, Development And Commercialization Agreement

* FIBROGEN - ON JULY 8, UNITS AND ASTRAZENECA ENTERED INTO AN AMENDMENT TO AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

BRIEF-FibroGen Announces First Patient Enrolled In Pamrevlumab Clinical Trial For Acute Covid-19

* FIBROGEN ANNOUNCES FIRST PATIENT ENROLLED IN PAMREVLUMAB CLINICAL TRIAL IN PATIENTS HOSPITALIZED IN U.S. WITH ACUTE COVID-19

BRIEF-Fibrogen Announces New Roxadustat Data Presented At 2020 Era-Edta Virtual Congress

* FIBROGEN ANNOUNCES NEW ROXADUSTAT DATA PRESENTED AT 2020 ERA-EDTA VIRTUAL CONGRESS

BRIEF-Fibrogen Says First Patient Enrolled In COVID-19 Trial In Italy

* FIBROGEN ANNOUNCES FIRST PATIENT ENROLLED IN PAMREVLUMAB CLINICAL TRIAL IN PATIENTS HOSPITALIZED IN ITALY WITH SEVERE COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Fibrogen Says UK High Court Of Justice Has Held Certain Patents Relating To Methods Of Using HIF-PHIs To Be Invalid

* FIBROGEN - UK HIGH COURT OF JUSTICE HAS HELD CERTAIN PATENTS RELATING TO METHODS OF USING HIF-PHIS TO BE INVALID

BRIEF-Fibrogen Inc Signs Agreement For Bulk Manufacture/Supply Of Roxadustat

* FIBROGEN INC - AGREEMENT WITH SHANGHAI SYNTHEALL PHARMACEUTICAL CO LTD, STA PHARMACEUTICAL HONG KONG LIMITED FOR BULK MANUFACTURE/SUPPLY OF ROXADUSTAT

China first to approve AstraZeneca, FibroGen anaemia drug

China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up